Core Viewpoint - The announcement by Heptares Therapeutics regarding its subsidiary Nona Biosciences entering a non-exclusive licensing agreement with Pfizer to advance preclinical antibody discovery for various potential disease indications [1] Group 1: Agreement Details - Nona Biosciences grants Pfizer global rights to utilize its proprietary HCAb platform for the development of fully human only heavy chain antibodies [1] - Nona Biosciences will receive an upfront payment and is entitled to regulatory, clinical, and commercial milestone payments [1] - The collaboration allows Nona Biosciences to leverage its HCAb platform, advanced B cell screening technology, and comprehensive services for antibody discovery, development, and engineering [1]

Core Viewpoint - The announcement highlights a strategic partnership between the company’s subsidiary, Nona Bio, and Pfizer to advance preclinical antibody discovery for various potential disease indications [1] Group 1: Agreement Details - Nona Bio has entered into a non-exclusive licensing agreement with Pfizer, granting Pfizer global rights to utilize Nona Bio's proprietary HCAb platform for the development of fully human only heavy chain antibodies [1] - Nona Bio will receive an upfront payment and is entitled to receive regulatory, clinical, and commercial milestone payments as part of the agreement [1] Group 2: Collaboration Aspects - The collaboration allows Nona Bio to work with Pfizer, leveraging its HCAb platform, advanced B cell screening technology, and comprehensive services for antibody discovery, development, and engineering [1]

Core Viewpoint - The announcement highlights a non-exclusive licensing agreement between Nona Bio, a wholly-owned subsidiary of HAPO (02142), and Pfizer to advance preclinical antibody discovery for various potential disease indications [1] Group 1: Agreement Details - Pfizer will gain global rights to utilize Nona Bio's proprietary HCAb platform for the development of fully human only heavy chain antibodies [1] - Nona Bio will receive an upfront payment and is entitled to regulatory, clinical, and commercial milestone payments [1] - The collaboration allows Nona Bio to leverage its HCAb platform, advanced B cell screening technology, and comprehensive services for antibody discovery, development, and engineering [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 和鉑醫藥控股有限公司 HBM Holdings Limited （於開曼群島註冊成立的有限公司） 根據協議條款，輝瑞將獲得諾納生物專有HCAb平台的全球使用權，以開發全人 源僅重鏈抗體。諾納生物將獲得首付款，並有權獲得監管、臨床及商業里程碑付 款。此外，諾納生物可與輝瑞合作，利用諾納生物的HCAb平台、先進的B細胞篩 選技術及綜合服務開展抗體發現、開發及工程。 警示聲明 我們無法保證我們或合作夥伴將能成功開發或最終銷售本公告所提述的任何候選 產品。本公司股東及潛在投資者於買賣本公司股份時務請審慎行事。 承董事會命 和鉑醫藥控股有限公司 主席兼執行董事 王勁松博士 （股份代號：02142） 自願公告 與輝瑞訂立非獨家授權協議 本公告由和鉑醫藥控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願 作出，以告知本公司股東及潛在投資者有關本集團的最新業務更新。 本公司董事會（「董事會」）欣然宣佈，本公司 ...